000			01390 a2200373 4500
005			20250517022746.0
264		0	_c20150615
008			201506s 0 0 fre d
022			_a1769-6917
024	7		_a10.1016/j.bulcan.2015.02.007 _2doi
040			_aNLM _beng _cNLM
100	1		_aGuerin, Mathilde
245	0	0	_a[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. _h[electronic resource]
260			_bBulletin du cancer _cApr 2015
300			_a390-7 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdo-Trastuzumab Emtansine
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aDrug Approval
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMaytansine _xanalogs & derivatives
650	0	4	_aNeoplasm Proteins _xmetabolism
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aReceptor, ErbB-2 _xmetabolism
650	0	4	_aTrastuzumab
700	1		_aSabatier, Renaud
700	1		_aGonçalves, Anthony
773	0		_tBulletin du cancer _gvol. 102 _gno. 4 _gp. 390-7
856	4	0	_uhttps://doi.org/10.1016/j.bulcan.2015.02.007 _zAvailable from publisher's website
999			_c24724533 _d24724533